Uma análise sobre as cardiomiopatias: hipertrófica e dilatada

##plugins.themes.bootstrap3.article.main##

Letícia Campitelle Perri Ribeiro
Rodrigo Maia Santos Felippe
Marianna Ramalho de Sousa
Ester Tannus Marques da Fonseca
Vanessa da Silva Baptista
Emílio Conceição de Siqueira

Resumo

Objetivo: Analisar as características das Cardiomiopatias Hipertrófica (CMH) e Dilatada (CMD). Revisão bibliográfica: As cardiomiopatias são doenças intrínsecas do coração caracterizadas por alteração estrutural do miocárdio, com etiologias tanto genéticas quanto adquiridas. Pacientes portadores de cardiomiopatia hipertrófica ou dilatada podem apresentar-se desde assintomáticos até intenso comprometimento das atividades diárias, com manifestações clínicas importantes como dispneia, dor no peito, fadiga, edema periférico, palpitações, arritmias e, em casos mais graves, até morte súbita cardíaca. A prevalência média dessas condições na população mundial é de 1:250 a 1:500 em adultos, apesar da expressão da doença ocorrer mais frequentemente em jovens. Essas condições afetam a contratilidade cardíaca e hemodinâmica, e, dependendo da extensão do comprometimento miocárdico, podem prejudicar severamente a qualidade de vida dos pacientes. Considerações finais: A cardiomiopatia hipertrófica caracteriza-se pelo aumento da espessura do ventrículo esquerdo. Já a cardiomiopatia dilatada é definida pela dilatação do ventrículo esquerdo ou biventricular, com prejuízo na fração de ejeção. Nesse contexto, o conhecimento sobre tais patologias mostra-se essencial a fim de promover diagnóstico e terapêutica adequada, proporcionando qualidade de vida aos pacientes.

##plugins.themes.bootstrap3.article.details##

Como Citar
RibeiroL. C. P., FelippeR. M. S., SousaM. R. de, FonsecaE. T. M. da, BaptistaV. da S., & SiqueiraE. C. de. (2022). Uma análise sobre as cardiomiopatias: hipertrófica e dilatada. Revista Eletrônica Acervo Saúde, 15(8), e10740. https://doi.org/10.25248/reas.e10740.2022
Seção
Revisão Bibliográfica

Referências

1. AKHTAR M, ELLIOTT PM. Risk Stratification for Sudden Cardiac Death in Non-Ischaemic Dilated Cardiomyopathy. Current Cardiology Reports, 2019; 21(12): 155.

2. ARGIRO A, et al. Sex-Related Differences in Genetic Cardiomyopathies. Journal of American Heart Association, 2022; 11: e024947.

3. BECKER MAJ, et al. The Prognostic Value of Late Gadolinium-Enhanced Cardiac Magnetic Resonance Imaging in Nonischemic Dilated Cardiomyopathy: A Review and Meta-Analysis. JACC: Cardiovascular Imaging, 2018; 11(9): 1274-1284.

4. BRAUNWALD E. Cardiomyopathies: An Overview. Circulation Research, 2017; 121: 711-721.

5. BRIELER J, et al. Cardiomyopathy: An Overview. Am Fam Physician, 2017; 96(10): 640-646.

6. COJAN-MINZAT BO, et al. Non-ischemic dilated cardiomyopathy and cardiac fibrosis. Heart Failure Review, 2021; (5): 1081-1101.

7. DYBRO AM, et al. Randomized Trial of Metoprolol in Patients with Obstructive Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2021; 78(25): 2505-2517.

8. ENZAN N, et al. The use of angiotensin II receptor blocker is associated with greater recovery of cardiac function than angiotensin-converting enzyme inhibitor in dilated cardiomyopathy. ESC Heart Failure, 2022; 9(2): 1175-1185.

9. GLUCKMAN TJ. Hypertrophic Cardiomyopathy: Diagnosis and Therapeutic Options. Am J Manag Care, 2021; 27(6): 111-117.

10. HABIB M, et al. Temporal Changes in Cardiac Morphology and Its Relationship with Clinical Characteristics and Outcomes in Patients with Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2022; 176: 125-131.

11. HALAND T, EDVARDSEN T. The role of echocardiography in management of hypertrophic cardiomyopathy. Journal of Echocardiography, 2020; 18: 77-85.

12. LONG C, et al. Sex Differences in Dilated Cardiomyopathy Prognosis. International Heart Journal, 2022; 63(1): 36-42.

13. MAISCH B, PANKUWEIT S. Inflammatory dilated cardiomyopathy. Herz Cardiovascular Diseases, 2020; 45: 221-229.

14. MARIAN AJ, BRAUNWALD E. Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. Circulation Research, 2017; 121(7): 749-770.

15. MARON BJ. Clinical Course and Management of Hypertrophic Cardiomyopathy. New England Journal of Medicine, 2018; 379: 655-668.

16. MCKENNA WJ, et al. Classification, Epidemiology, and Global Burden of Cardiomyopathies. Circulation Research, 2017; 121: 722-730.

17. MCNALLY EM, MESTRONI L. Dilated cardiomyopathy: genetic determinants and mechanisms. Circulation Research, 2018; 121(7): 731-748.

18. MEDICAL MASTERCLASS, FIRTH J. Cardiology: hypertrophic cardiomyopathy. Royal College of Physicians, 2019; 19(1): 61-63.

19. MERLO M, et al. Evolving concepts in dilated cardiomyopathy. European Journal of Heart Failure, 2017; 20(2): 228-239.

20. ORPHANOU N, et al. Dilated cardiomyopathy in the era of precision medicine: latest concepts and developments. Heart Failure Reviews, 2021; 27(4): 1173-1191.

21. PETERS S, et al. Familial Dilated Cardiomyopathy. Heart Lung Circulation, 2020; (4): 566-574.

22. RANJBARVAZIRI S, et al. Altered Cardiac Energetics na Mitochondrial Dysfunction in Hypertrophic Cardiomyopathy. Circulation, 2021; 144: 1714-1731.

23. REICHART D, et al. Dilated cardiomyopathy: from epidemiologic to genetic phenotypes. Journal of Internal Medicine, 2019; 286(4): 362-372.

24. ROMANO MMD. Ecocardiograma Guiando Tratamento Percutâneo de Cardiomiopatia Hipertrófica Obstrutiva: Navegar (em Águas Conhecidas) e preciso. Arquivo Brasileiro de Cardiologia, 2022; 118(5): 873-874.

25. SAROHI V, et al. A Comprehensive Outlook on Dilated Cardiomyopathy (DCM): State-Of-The-Art Developments with Special Emphasis on OMICS-Based Approaches. Journal of Cardiovascular Development and Disease, 2022; 9(6): 174.

26. SCHULTHEISS HP, et al. Dilated cardiomyopathy. Nature Reviews Disease Primers, 2019; 5(1): 32.

27. SINAGRA G, et al. Risk stratification in cardiomyopathy. European Journal of Preventive Cardiology, 2020; 27(2): 52-58.

28. TAYAL U, et al. Precision Phenotyping of Dilated Cardiomyopathy Using Multidimensional Data. American Journal of Cardiology, 2022; 79(22): 2219-2232.

29. YOUNG L, et al. Hypertrophic cardiomyopathy: A complex disease. Cleveland Clinic Journal of Medicine, 2018; 85 (5): 399-411.

30. ZEGKOS T, et al. Mitral regurgitation impact on left atrial myopathy in hypertrophic cardiomyopathy. Echocardiography, 2022; 39(6): 819-826.